Detecting Substance Abuse in Mental Health Patients: Tools and Techniques

When a patient arrives at a psychiatric emergency unit displaying altered mental status, aggressive behavior, or psychotic symptoms, clinicians face an immediate challenge: is this a primary mental illness, substance intoxication, or a dangerous mix of both? The answer isn’t always obvious from symptoms alone. That’s where physical investigations like breath analyzers and urine drug screens become indispensable. These tools give clinicians objective, real-time data to cut through diagnostic uncertainty and guide appropriate treatment – quickly and safely.

Breath analyzers for alcohol detection 🔗

Alcohol is among the most commonly misused substances in patients presenting to psychiatric settings. A breath analyzer – often called a breathalyzer – measures the amount of alcohol in exhaled air to estimate blood alcohol content (BAC). The principle behind it is straightforward: a well-established physiological relationship exists between the concentration of alcohol in pulmonary blood and in exhaled breath, making breath sampling a noninvasive and clinically attractive alternative to blood tests.

When a person consumes alcohol, it is absorbed from the stomach and small intestine into the bloodstream, eventually reaching the lungs. The device uses the measurement of alcohol in exhaled air to estimate BAC, which may begin rising as soon as 15 minutes after drinking and typically peaks around one hour after consumption. In clinical practice, this speed is a major advantage.

Use in uncooperative or psychotic patients 🔗

One of the most important applications in psychiatric settings is assessing patients who cannot or will not provide reliable histories – including those who are agitated, psychotic, or combative. Standard fuel-cell breathalyzers can obtain readings even from patients who are unable to cooperate fully. Research has confirmed that the Alco-Sensor III breath alcohol analyzer is sufficiently accurate to assess blood alcohol levels even when a patient is unable to cooperate fully, with nasal sampling as an option when a full exhalation is not possible.

Breathalyzer readings are routinely relayed to hospital staff from pre-hospital providers, and elevated readings may help explain altered mental status in the emergency department and trauma bay. In a patient presenting with apparent psychosis, for instance, a high BAC can immediately suggest acute alcohol intoxication as a contributing or primary cause – altering the treatment approach significantly.

How the device works and its limitations 🔗

Most professional breath analyzers use fuel cell technology, which converts detected alcohol into an electrical current proportional to its concentration. There are two main types used clinically: preliminary alcohol screening (PAS) tests – small handheld devices – and evidential breath tests (EBTs), which are larger, stationary, and more accurate. For clinical decision-making in psychiatric emergencies, the handheld PAS device is practical and fast, though positive findings are ideally confirmed by EBT or blood alcohol level.

Clinicians must also be aware of variables that can skew results. Drinking water and hyperventilation have both been shown to significantly alter breath alcohol content readings, producing falsely lower values. Mouth alcohol from recent food, mouthwash, or vomiting can produce falsely high readings. For this reason, clinical guidelines generally recommend observing a patient for at least 15-20 minutes prior to testing and interpreting results within the full clinical context rather than in isolation.

Urine screens for drug abuse 🔗

While breath analyzers address alcohol, urine drug screens (UDS) cast a broader net. They are the most widely used method for detecting recent use of substances including cannabis, opioids, benzodiazepines, cocaine, and amphetamines. Urine testing is the best-developed and most commonly used monitoring technique in substance abuse treatment programs, valued for its non-invasive nature, quick turnaround, and relatively low cost.

Urine drug tests are easy to administer, costs are lower than for other types of drug testing, results are near-instant, and proprietary dipstick tests mean that a laboratory or technician is not always essential – making them a practical first-choice tool in mental health services for frequent, random testing.

What urine screens detect and how 🔗

Standard urine drug screens use immunoassay (IA) technology, which identifies the presence of drug metabolites in the urine. A basic five-panel screen typically covers amphetamines, benzodiazepines, opiates, cocaine, and cannabinoids (THC). Expanded panels add substances like fentanyl, methadone, barbiturates, and tricyclic antidepressants. The five-panel screen evaluates for the presence of amphetamines, benzodiazepines, opiates, cocaine, and cannabinoids, while the expanded panel includes tricyclics, fentanyl, barbiturates, methadone, and PCP in addition.

Detection windows vary by substance. Cannabis metabolites may be detectable for days to several weeks in heavy users, making it particularly useful for confirming chronic use. Opioids and benzodiazepines typically remain detectable for two to four days, while cocaine metabolites are usually cleared within two to three days. These windows make UDS most useful for identifying recent use rather than acute intoxication.

Clinical application in diagnosis and treatment 🔗

In psychiatric settings, the UDS plays a crucial diagnostic role. Many mental disorders share symptom profiles with substance intoxication or withdrawal – psychosis, anxiety, mood dysregulation, and cognitive impairment can all stem from drug use. A positive urine screen can redirect a diagnosis, prevent misattribution of symptoms to a primary psychiatric condition, and avoid unnecessary or contraindicated medications.

Drug tests are commonly used in emergent situations, such as when an adolescent presents with altered mental status, including attempted suicide, motor vehicle injury, unexplained seizures, syncope, arrhythmia, or toxidromal signs suggesting a particular intoxication or withdrawal pattern. In such cases, the UDS provides objective data that supplements clinical observation.

However, UDS results must always be interpreted with care. Immunoassays can cross-react with other medications and give false-positive results, and false-negative results can lead to missed opportunities to detect misuse. For instance, standard opiate immunoassays may fail to detect synthetic opioids like fentanyl or oxycodone, and some benzodiazepine panels miss commonly prescribed agents like alprazolam and clonazepam. When clinical decisions hinge on an accurate result, confirmatory testing using gas chromatography/mass spectrometry (GC/MS) or liquid chromatography/mass spectrometry (LC/MS) is essential – these methods can identify individual drugs and their metabolites with much greater precision.

It is equally important to note that screening tests do not distinguish specific drug metabolites within a class and provide only qualitative results – a yes or no – rather than measuring degree of intoxication. A positive UDS for opioids, for example, does not reveal which opioid was taken, at what dose, or how recently. The test is best used as one piece of a larger clinical picture.

Legal and treatment applications 🔗

Beyond the emergency room and outpatient clinic, breath analyzers and urine screens serve important functions in de-addiction programs, legal proceedings, and long-term recovery monitoring. Their role in these contexts is dual: they provide accountability and they support therapeutic goals.

Monitoring abstinence in de-addiction programs 🔗

In substance use disorder treatment programs, drug testing is not punitive – it’s a clinical tool. Drug testing helps determine treatment adherence, monitor abstinence, and detect early relapse. When a patient in a de-addiction program undergoes regular urine screening, clinicians can track whether prescribed medications (such as methadone or buprenorphine for opioid use disorder) are being taken correctly and whether any non-prescribed substances are being used concurrently.

Clients generally need more frequent monitoring during initial stages of treatment when they are trying to achieve abstinence but may still be using substances. Once stabilized, programs typically reduce test frequency and randomize collection times. Scheduling tests on clinic days following weekends, holidays, or paydays – times when relapse risk is higher – is a widely used strategy to maximize clinical utility. According to the Mayo Clinic, a 50% reduction in substance misuse is reported when clinical urine drug testing is combined with other risk-mitigation strategies, underscoring its value as part of a comprehensive treatment approach rather than a standalone measure.

Relapse prevention and early warning 🔗

In institutional and community settings, drug testing can serve as an early warning device, helping detect problems among individuals in therapeutic residential programs and acting as a deterrent to use as well as a strong incentive for offenders to remain abstinent. A positive test at a critical juncture allows treatment teams to intervene early – adjusting medications, intensifying counseling, or addressing triggers – before a full relapse takes hold.

For alcohol specifically, alcohol abstinence conditions in supervised settings are monitored through random breathalyzer testing, often combined with contact with family members or associates who can observe behavioral changes. Early warning signs of imminent relapse – such as a sudden change in mood, renewed association with substance-using peers, or frequenting old drug-use locations – are identified and addressed through integrated testing and counseling.

Legal applications 🔗

Breath and urine tests carry significant weight in legal and forensic settings. Drug testing may be used as legal evidence, as part of a criminal or motor vehicle accident investigation, or ordered as part of a court case. In de-addiction courts and drug diversion programs, regular testing is often a condition of participation, and results can directly influence sentencing, supervision levels, and access to community-based services.

Major medical organizations including the American College of Physicians and the American Society of Addiction Medicine emphasize regular monitoring through urine drug testing as part of chronic opioid therapy programs and substance use disorder treatment, with frequency and type of testing tailored to individual risk levels. This risk-stratified approach – testing more frequently for high-risk patients and less so for stable, low-risk individuals – reflects a growing consensus that testing should be clinically guided, not reflexive.

Clinicians, legal professionals, and treatment providers must all interpret results in context. A positive screen is not a verdict; it is data. And a negative screen does not guarantee sobriety, given the limitations of detection windows and the potential for sample adulteration. Used thoughtfully alongside clinical assessment, self-report, and therapeutic alliance, these tools strengthen the entire system of care for individuals with substance use disorders.

What do you think? If a patient consistently denies drug use but urine screens repeatedly return positive, how should a clinician balance objective test results with the therapeutic relationship? And should substance screening be a routine part of all psychiatric assessments, or reserved for specific presentations?

References

1. https://www.sciencedirect.com/topics/nursing-and-health-professions/breath-alcohol-analyzer
2. https://www.webmd.com/mental-health/addiction/breath-alcohol-test
3. https://pubmed.ncbi.nlm.nih.gov/6742553/
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC7204959/
5. https://www.medicalnewstoday.com/articles/breathalyzer-test
6. https://www.ncbi.nlm.nih.gov/books/NBK64092/
7. https://www.cambridge.org/core/journals/advances-in-psychiatric-treatment/article/testing-for-illicit-drug-use-in-mental-health-services/65C1B23761FB0C702CDF88AE9B7EB77D
8. https://www.emra.org/emresident/article/urine-drug-screen
9. https://pmc.ncbi.nlm.nih.gov/articles/PMC4920965/
10. https://www.aafp.org/pubs/afp/issues/2019/0101/p33.html
11. https://my.clevelandclinic.org/health/diagnostics/10285-drug-testing
12. https://whitelightbh.com/resources/drug-addiction/urine-test/
13. https://www.ncbi.nlm.nih.gov/sites/books/NBK572940/
14. https://www.uscourts.gov/about-federal-courts/probation-and-pretrial-services/post-conviction-supervision/overview-probation-and-supervised-release-conditions/chapter-3-substance-abuse-treatment-testing-and-abstinence
15. https://medlineplus.gov/lab-tests/drug-testing/
16. https://www.anthem.com/medpolicies/abc/active/gl_pw_c166612.html